Big biotech, Biotech, Partnering

SciClone Pharmaceuticals signs biotech deals with Zensun for Neucardin

Posted on 20 May 2013

Tags: , ,

SciClone Pharmaceuticals has entered big biotech deals with Zensun Science & Technology granting SciClone the rights to promote, market, distribute and sell Neucardin in China, Hong Kong and Macau.

Neucardin is a novel, first-in-class therapeutic drug for the treatment of patients with intermediate to advanced congestive heart failure.

SciClone Pharmaceuticals, the big biotech company, entered biotech deals for Neucardin, which is a genetically engineered recombinant peptide fragment of neuregulin-1 that has been clinically shown to directly improve cardiac function, reverse ventricular remodeling and increase the survival of congestive heart failure patients.

Six Phase 2 studies with Neucardin have been conducted in China, Australia and the United States, including three Phase 2b studies in China.

The China Phase 2b survival study demonstrated that Neucardin was well tolerated and showed a significant decrease in mortality and improved survival in patients with CHF.

Under the terms of the biotech deals agreement, Zensun will be responsible for the manufacturing and supply of Neucardin, and SciClone Pharmaceuticals, the big biotech company, will be responsible for all aspects of commercialization, including the pre- and post-launch activities for Neucardin.

Financial terms of the biotech deals agreement include aggregate potential milestone payments of up to $18.5 million.

The Company has agreed to make additional payments of $10 million should Zensun receive approval of Neucardin by subcutaneous infusion as part of the biotech deals.

Further indications and improved product forms of Neucardin could result in additional payments.

Also included in the biotech deals agreement is a $12 million collateralized loan facility by which SciClone Pharmaceuticals would provide a secured loan to Zensun that Zensun may use in future.

For further deal information visit Current Agreements (subscription required)


Read: more on SciClone Pharmaceuticals company profile, recent partnering, M&A and financing news and articles

Report: Congestive Heart Failure Partnering

Report: Cardiovascular Partnering Terms and Agreements


View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value 

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making        

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity                  

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity 

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now                                

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now 

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more 

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply